Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 8, Issue 1, Pages 9-18Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2015.983065
Keywords
epigenetics; histone deacetylase inhibitors; immunomodulatory drugs; LBH589; multiple myeloma; panobinostat; proteasome inhibitors
Categories
Ask authors/readers for more resources
Multiple myeloma is an incurable often devastating disease that is responsible for 1-2% of all cancers. Multiple myeloma is the second most common hematologic malignancy. Over the past two decades, advances in therapy have doubled life expectancy. Unfortunately, all patients ultimately relapse. Novel agents (immunomodulatory drugs and proteasome inhibitors) have changed the outlook for patients, but further breakthroughs are needed. Epigenetic treatments offer potential for advancing therapy by modifying oncogene responses. The acetylation status of various proteins can affect the availability of chromatin for transcription. This response may be modulated epigenetically to advantage using histone deacetylase inhibitors like panobinostat.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available